SEC Filing Summary: Aikido Pharma Inc. (AIKI)
Business Context and Reporting Period
This Form 8-K Current Report, dated February 24, 2022, details a material definitive agreement entered into by Aikido Pharma Inc. (the "Company"). The filing announces a registered direct offering of preferred stock and a proposed reverse stock split of the Company's common stock.
Key Financial Metrics and Transaction Details
- Offering Proceeds: The Company agreed to sell 11,000 shares of Series O and 11,000 shares of Series P Redeemable Convertible Preferred Stock.
- Offering Price: $952.38 per share (representing a 5% original issue discount to the $1,000 stated value).
- Gross Proceeds: Approximately $21.9 million in the aggregate ($10,476,180 per series) before placement agent fees and expenses.
- Conversion Terms: Preferred stock is convertible at $1.00 per share into 11,000,000 shares of common stock per series (subject to adjustments).
- Placement Agent Fees: H.C. Wainwright & Company, LLC will receive an 8% cash fee, a 1% management fee, a $25,000 expense allowance, and warrants to purchase up to 1,760,000 shares of common stock at $1.25 per share.
- Liquidity: Proceeds are held in escrow until the expiration of the Redemption Period (90 to 120 days post-issue) or earlier redemption.
Material Changes and Strategic Actions
- Reverse Stock Split Proposal: The Company intends to propose a reverse stock split of its common stock at a ratio between 5-for-1 and 30-for-1 at its 2022 annual meeting.
- Voting Structure: Investors have agreed to vote their Series O and Series P shares to approve the reverse stock split. Series P shares carry 30,000 votes per share but will "mirror" the voting proportions of common stockholders to ensure the split passes.
- Issuance Lock-up: Until the earlier of 120 days post-closing or the reverse stock split date, the Company is prohibited from issuing new common stock or equivalents (with certain exemptions).
- Redemption Rights: Holders may redeem shares for 105% of the stated value plus accrued dividends during a specific window (90 to 120 days after the original issue date).
Guidance, Risks, and Contingencies
- Closing Date: The closing of the offerings is expected on March 2, 2022.
- Contingency: The conversion of preferred stock to common stock is contingent upon stockholder approval of the reverse stock split and the filing of the requisite amendment.
- Risk Factors: The filing notes that the purchase agreement representations are for the benefit of the parties only and do not constitute factual information about the Company's business outside the agreement terms.
- Unusual Items: The transaction involves a complex dual-class preferred stock structure designed specifically to facilitate a reverse stock split while raising capital.
Investor Verification Checklist
- Verify the final ratio of the proposed reverse stock split (currently proposed as a range of 5-1 to 30-1).
- Confirm the actual closing date of the offering and the disbursement of escrowed funds.
- Review the impact of the 11,000,000 shares of common stock issuable upon conversion of each series on existing shareholder dilution.
- Monitor the outcome of the shareholder vote on the reverse stock split at the 2022 annual meeting.
- Check for any subsequent filings regarding the redemption of preferred stock during the 90-120 day window.